key: cord-272015-1anph6qi
authors: Dauby, Nicolas; Bottieau, Emmanuel
title: The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?
date: 2020-10-17
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.10.032
sha: 
doc_id: 272015
cord_uid: 1anph6qi

nan

Dear Editor, Uncontrolled inflammation, partly related to activated macrophages, is widely recognized as an independent cause of clinical deterioration and mortality in hospitalised patients (Webb et al.; Del Valle et al. 2020) . Following the results of the RECOVERY trial and of an additional meta-analysis, corticosteroids are now recommended as a standard of care for hospitalized patients with severe and critical COVID-19 (WHO 2020). Importantly, the benefit of this anti-inflammatory intervention has been observed with a low dose of dexamethasone, while observational studies using higher dosage of corticosteroids have not reported any favourable effect on mortality (Hasan et al. 2020) .

The observation by Lammers et al (Lammers et al.) that early HCQ treatment after admission at low dosage (2400 mg in total) is associated with lower risk of admission in intensive care unit coincides with large observational studies showing a lower mortality rate in patients exposed to HCQ therapy compared to no or other treatment. Of note, in all these studies and in contrast to the RECOVERY trial, low doses of HCQ (< 2.5 gr. in total) were used, often soon after admission (Arshad et al. 2020; Ayerbe et al. 2020; Catteau et al. 2020; COVID-19 RISK and Treatments (CORIST) Collaboration 2020). Another recent large cohort study of patients on low-dose HCQ for inflammatory disorders reported an association between chronic HCQ use and reduced mortality following SARS-CoV-2 infection (Gentry et al. 2020) .

As highlighted by the findings of Lammers et al, the timing of HCQ therapy (administration within 1 day of admission) could explain discrepancies between different studies. In the RECOVERY trial, the median time between symptoms onset and randomization was 9 days J o u r n a l P r e -p r o o f and a substantial proportion of patients (16.7%) was already on mechanical ventilation at randomization(The RECOVERY Collaborative Group 2020).

HCQ has been used as anti-inflammatory drug for decades as therapy of inflammatory disorders and its impact on inflammatory responses is well documented. HCQ inhibits the production of the pro-inflammatory cytokines interleukin (IL)-6, TNF-α and IL-1-β by activated macrophages (Sperber et al. 1993; Jang et al. 2006) , which are notoriously associated with COVID-19 severity (Webb et al.; Del Valle et al. 2020 ) and also the production of chemotactic cytokines involved in the recruitment of pro-inflammatory cells in the lungs(Grassin-Delyle et al. 2020). In line with this, an Italian study suggests that the benefit of HCQ was restricted to patients with elevated C-reactive protein levels(COVID-19 RISK and Treatments (CORIST) Collaboration 2020).

Thrombotic events are another well recognized complication of severe COVID-19 (Llitjos et al. 2020 ) and the presence of lupus anticoagulant has been reported in hospitalised COVID-19 (Bowles et al. 2020) . HCQ therapy has been associated with a decrease of lupus anticoagulant levels as well as of platelet activation and thrombotic events in lupus patients (Broder and Putterman 2013) . Interestingly, B cell abnormalities similar to those reported in autoimmune disease such as active lupus were reported in patients with severe COVID-19 (Woodruff et al. 2020 ).

HCQ has no antiviral activity in vivo against SARS-CoV-2 as shown in pre-clinical models such as Syrian hamsters, non-human primates and human lung cells, and should therefore not be used as antiviral therapy in COVID-19 (Maisonnasse et al. 2020) . However, to further understand the positive effects observed in large observational studies that used HCQ offlabel in the early months of the pandemic, the hypothesis of an anti-inflammatory action J o u r n a l P r e -p r o o f 4 should not be discarded. We suggest that ongoing trials evaluating HCQ specifically look at its effect on inflammatory parameters with add-on studies if necessary. In the same line, ongoing trials are investigating colchicine to prevent hospitalisation in SARS-CoV-2 infected subjects, and the rationale is based on anti-inflammatory properties, that are partly shared 

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients

Hydroxychloroquine: from malaria to autoimmunity

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus

Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

An inflammatory cytokine signature predicts COVID-19 severity and survival

Longterm hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study

Chloroquine inhibits the release of inflammatory cytokines by human lung explants

Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis

Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes

Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Colchicine as a possible therapeutic option in COVID-19 infection

Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

World Health Organization

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19